Table 2.

Summary of raltegravir PK parameters following administration of final recommended doses in IMPAACT Protocol 1066

Age	Cohort	Formulation	Final Recommen ded Dose	N*	Mean (%CV) Weight (kg)	Mean (%CV) Dose (mg/kg)	Observed Geometric Mean (%CV) AUC0-12hr (μM-hr)	Simulated Geometric Mean (%CV) AUC0-12hr (μM-hr)	Observed Geometric Mean (%CV) C12h (nM)	Simulated Geometric Mean (%CV) C12hr (nM)
6 months to <2 years	IV	Granules for suspension	6 mg/kg twice daily	8	8.5 (34)	5.9 (7)	19.8 (34)	18.5 (34)	108.2 (52)	149.1 (88)
4 weeks to <6 months	V	Granules for suspension	6 mg/kg twice daily	11	5.5(22)	5.7 (12)	22.3 (40)	21.6 (47)	116.6 (68)	140.0 (117)

^*Number of patients with intensive PK results at the final recommended dose